G3T Therapeutics
G3T is developing assets in cardio-metabolic, metabolic and cardiovascular diseases, such as non-alcoholic steatohepatitis (NASH), obesity, diabetes, atherosclerosis, etc. We define our assets as genetically validated drug targets. We partner with pharmaceutical, biopharmaceutical and biotechnology companies on specific assets. We also enter into broad discovery-based partnerships related to specific disease states, such as diabetes or obesity. In addition, we can assist clients and partners by validating their own targets based on the G3T platform, and by identifying companion and complimentary diagnostics that may predict a better response to specific drugs.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About us
G3T is a pre-clinical stage biotechnology company developing novel therapeutic approaches for serious diseases that cause significant individual suffering and societal burden.
We are an innovative biopharmaceutical company, trailblazing the use of deep, panomic biological big data for drug discovery and development.
We are developing revelationary therapeutics enabled by our own, prospectively collected, deep biological big data, analyzed through visionary machine learning (ML) and artificial intelligence (AI) approaches.
There are genomics companies, epigenetics companies, transciptomics companies, proteomics companies, imaging companies, and AI/ML companies... G3T combines expertise from all of these disciplines to provide a unique solution.
What we do
We rejuvenate drug discovery by combining highly quantitative, deep phenotyping data from humans with a comprehensive, panomic molecular profiling approach, using unbiased, hypothesis-free bioinformatics and AI tools to unravel novel biology and translate it into breakthrough new therapies. We anchor our novel therapeutics in human genetic target validation.
Genetic target validation increases the odds of a successful launch by a factor of five.